Full-Time
Develops cardiac myosin inhibitors for HCM
$195k - $230k/yr
San Francisco, CA, USA
Hybrid
Hybrid role with on-site days in San Francisco; remote option listed but not 100% remote.
Bachelor's, Master's, PhD
See people who can refer or advise you
Braveheart Bio develops therapeutics for hypertrophic cardiomyopathy by in-licensing and advancing late-stage drug candidates. Its lead drug, BHB-1893, is a selective small-molecule cardiac myosin inhibitor licensed from Hengrui Pharma for ex-China rights in a deal worth up to $1.1 billion, aimed at improving heart function by tempering myosin activity in HCM. The program includes Phase 2 trials in obstructive and non-obstructive HCM and a Phase 3 trial in China, with global late-stage development planned to begin in 2026. The company differentiates itself by pursuing a best-in-class profile with better efficacy, safety, and dosing, supported by a strong leadership team and high-profile investors, with the goal of delivering an approved therapy that provides meaningful clinical benefit and broader global access.
Company Size
11-50
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2025
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Flexible Work Hours
Company Equity
Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3. Biotech correspondent. For the second time this year, a US biotech born out of the pipeline of China-based Hengrui Pharmaceuticals is going public on the Nasdaq. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Braveheart Bio, a clinical-stage biopharmaceutical company developing therapeutics for hypertrophic cardiomyopathy and other cardiovascular diseases, has priced its upsized initial public offering at $18.00 per share. The San Francisco-based company is offering 21,250,000 shares, with expected gross proceeds of $382.5 million before deducting underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Market on 6 August 2026 under the ticker symbol "BRVE". The offering is scheduled to close on 7 August 2026, subject to customary closing conditions. Braveheart Bio has granted underwriters a 30-day option to purchase up to an additional 3,187,500 shares. Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor are serving as joint book-running managers.
Braveheart Bio has appointed Emil deGoma, M.D., as Chief Medical Officer to lead clinical strategy and medical affairs as the company advances BHB-1893 towards a planned global pivotal trial in obstructive hypertrophic cardiomyopathy in 2026. DeGoma joins from Tourmaline Bio, where he served as Senior Vice President of Medical Research. He previously held leadership positions at Akebia Therapeutics, overseeing cardiovascular outcomes trials with over 7,000 patients, and at ChemoCentryx and Penn Medicine. He completed his cardiovascular medicine fellowship at Stanford University and is a Fellow of the American College of Cardiology. Braveheart Bio is a clinical-stage biotechnology company backed by investors including Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences and Frazier Life Sciences.
Emil deGoma named Braveheart CMO. 26 March 2026 Braveheart Bio, a US biotech developing therapeutics for hypertrophic cardiomyopathy (HCM) and related cardiovascular conditions, has announced the appointment of Emil deGoma (pictured, above) as chief medical officer (CMO). This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 5 February 2026 6 November 2025 13 March 2026 Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 29 March 2026 28 March 2026 27 March 2026 Company spotlight. A biotech firm developing a novel class of allergy therapies known as Trifunctional Effector Cell Response Inhibitors (ECRIs). More features in biotechnology. 28 March 2026 27 March 2026
Braveheart Bio has appointed Marc Evanchik as Chief Scientific Officer and Brittany de Temple as Senior Vice President of Development Operations as it prepares for a planned global Phase 3 trial in obstructive hypertrophic cardiomyopathy in 2026. Evanchik, promoted from his previous role, brings over 25 years of biotech experience and was instrumental in advancing Camzyos, the first-in-class cardiac myosin inhibitor. He will lead scientific strategy from target discovery through late-stage development for the company's lead programme, BHB-1893. De Temple joins from Akero Therapeutics with more than 20 years of clinical development operations experience. She will oversee operational strategy and execution of Braveheart's expanding clinical programmes. The San Francisco-based company is backed by investors including Andreessen Horowitz and OrbiMed.